Articles

Vantage logo

The scramble to reinvent the ventilator

As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.

Vantage logo

Amarin falls at obvious hurdle

Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.

Vantage logo

Vantage's coronavirus roundup

All of Vantage's Covid-19 stories in one place: share price reactions, clinical trial delays, cost estimates, and more. This page will be updated as our coverage…

Vantage logo

Covid-19 forces Lilly to hit the brakes

As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.